🇺🇸 FDA
Patent

US 11033539

Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases

granted A61KA61K31/444A61K31/4545

Quick answer

US patent 11033539 (Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases) held by Neurocrine Biosciences, Inc. expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/444, A61K31/4545, A61K31/496, A61K31/506